Impedimed Limited
(ASX:IPD) says another world-leading hospital has joined its L-Dex post approval trial.
The L-Dex technology helps physicians and surgeon detect changes in cellular fluid levels to detect lymphadema post-surgery.
The prestigious Mayo Clinic in Jacksonville Florida has now joined the list of National Cancer Institute of cancer centres in the international trial.
Impedimed reported a net loss of $6.1 million for the full year ending 31 December 2014.
